Please login to the form below

Not currently logged in
Email:
Password:

Astellas picks Dr Charlotte Kremer to lead new medical affairs organisation

She joins the pharma company from Pfizer to take up a new global role

Astellas Dr Charlotte KremerDr Charlotte Kremer has moved from Pfizer to Astellas to lead the Japanese pharma company's new global medical affairs organisation.

Based at Astellas' Illinois headquarters for its Americas operations, Dr Kremer will be tasked with providing “global leadership for medical excellence and a unified medical perspective”.

The company's Global Medical Affairs unit is one of its newest organisations and, although based in the US, may work with a variety of supporting positions from across the regions in which Astellas is active.

"We are thrilled to have Charlotte join Astellas. She brings years of experience and an outstanding reputation to this new, global leadership role," said Yoshihiko Hatanaka, president and CEO of Astellas Pharma Inc., the parent company of Astellas US LLC.

"Further globalising our key functions, such as medical affairs, is a top priority at Astellas because of the value it brings to the company in this competitive global business environment."

Dr Kremer has spent 20 years in the pharmaceutical industry, most recently serving at Pfizer as VP and therapeutic area head for ophthalmology, PVD, rare diseases and neuroscience.

Prior to joining Pfizer she worked at Organon in the Netherlands and the US, providing medical support, developing phase IIIb/IV clinical trials and initiated and developed a medical liaison programme.

23rd February 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...

Infographics